← All trials
NCT06617715
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 12, 2024
- Primary completion
- Mar 12, 2025
- Completion date
- Apr 12, 2026
- First posted
- Sep 27, 2024
- Last posted
- Sep 27, 2024
- Enrollment
- 3975
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- China National Pharmaceutical GroupLead sponsor
- Government of ChinaOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.